Frank Mottola - 18 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: SVP, Chief Tech. Ops. Officer
Issuer ticker: SUPN
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 16:46:49 UTC
Prior SEC filing: 22 Dec 2025
Next SEC filing: 25 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

Frank Mottola filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 20 Feb 2026.

Key facts

This page summarizes Frank Mottola's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 20 Feb 2026, 16:46.

Change

Previous filing in this sequence was filed on 22 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001804567 Primary reporting owner

Mottola Frank

Relationship: SVP, Chief Tech. Ops. Officer
Address: C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 15,724
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +13,500
Change %
Price: $0.000000
Shares after: 13,500
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,500
Exercise price: $50.20
Footnotes: F2

SUPN transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +3,000
Change %
Price: $0.000000
Shares after: 3,000
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Includes an aggregate of 228 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

Footnote F2

The option vests in four equal annual installments beginning on February 18, 2027.

Footnote F3

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F4

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.